Kancera Logo

Kancera

Pharmaceutical company seeking a reverse takeover to leverage its public listing.

KAN | ST

Overview

Corporate Details

ISIN(s):
SE0015658570 (+1 more)
LEI:
5493002P3RCOFW6HI207
Country:
Sweden
Address:
Nanna Svartz väg 4, 171 65 SOLNA

Description

Novakand Pharma AB, formerly Kancera AB, is a pharmaceutical company that was focused on the development of small molecule therapeutics. Its primary research areas included cancer and inflammatory diseases. The company's pipeline featured drug candidates targeting the fractalkine system for cardiovascular and inflammatory conditions, as well as ROR inhibitors for oncology applications such as leukemia and solid tumors. Following a strategic review prompted by challenging capital market conditions, the company has initiated a process to seek a reverse takeover, aiming to leverage its public listing and cash assets for a merger with another entity.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Kancera filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kancera

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kancera via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Transgene Logo
Develops cancer immunotherapies using vaccines and oncolytic viruses.
France
TNG
TRANS GENIC GROUP INC. Logo
Biotech firm offering drug discovery support and investment/consulting services.
Japan
2342
TriSalus Life Sciences, Inc. Logo
Oncology company integrating drug delivery with immunotherapy to treat solid tumors.
United States of America
TLSI
TScan Therapeutics, Inc. Logo
A clinical-stage biotech developing TCR-engineered T cell therapies for cancer.
United States of America
TCRX
Tsubota Laboratory Incorporated Logo
R&D company developing treatments for ophthalmology and CNS disorders.
Japan
4890
TuHURA Biosciences, Inc./NV Logo
A Phase 3 immuno-oncology company developing therapies for immunotherapy resistance.
United States of America
HURA
Tyra Biosciences, Inc. Logo
Clinical-stage biotech developing precision medicines targeting FGFR biology.
United States of America
TYRA
UCAR Logo
A nonprofit consortium of universities advancing atmospheric and Earth system sciences.
France
ALUCR
Ulisse Biomed Logo
Develops an integrated platform for distributed and connected diagnostic solutions.
Italy
UBM
UNIVERSAL DISPLAY CORP \PA\ Logo
Researches, develops, and supplies OLED technologies and materials for displays.
United States of America
OLED

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.